Calfactant: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Calfactant. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Apnea | 61% |
| Patent ductus arteriosus | 48% |
| Intracranial hemorrhage | 31% |
| Sepsis | 22% |
| Pulmonary air leaks | 22% |
| Pulmonary interstitial emphysema | 17% |
| Pulmonary hemorrhage | 7% |
| Necrotizing enterocolitis | 5% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
INFASURF is indicated: to reduce the risk of respiratory distress syndrome (RDS) in preterm neonates <29 weeks of gestational age at risk for RDS. for the rescue treatment of RDS in preterm neonates ≤72 hours of age with RDS who require endotracheal intubation.
Source: FDA labeling via NIH DailyMed (set 315c128a…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.